Baricitinib and ritlecitinib in alopecia areata: A nationwide prospective real-world registry study.

Observational OA: gold CC-BY-4.0
📄 Open PDF View on PubMed View at publisher

Abstract

BackgroundJanus kinase inhibitors baricitinib and ritlecitinib are approved for the treatment of severe alopecia areata (AA). However, prospective real-world data on effectiveness, disease burden, and tolerability are limited.ObjectiveTo evaluate the real-world effectiveness and tolerability of baricitinib and ritlecitinib in adults with AA.MethodsIn this nationwide, prospective, multicenter registry (Systemic Treatments for Alopecia Areata Registry), adults initiating baricitinib or ritlecitinib between January 2024 and April 2026 were included. The primary outcome was Severity of Alopecia Tool (SALT) score trajectory over 12 months, analyzed using a linear mixed model adjusted for baseline SALT score, AA subtype, age, sex, atopic history, disease duration, prior treatment response, and prior Janus kinase inhibitor use.ResultsA total of 166 patients were included (baricitinib, n = 106; ritlecitinib, n = 60). SALT scores declined significantly over time in both groups (β = -4.22 points/mo), with no significant difference between treatments. At 12 months, adjusted SALT scores were 33.7 for baricitinib and 33.4 for ritlecitinib, with SALT ≤20 achieved by 30 of 47(64%) and 12 of 24(50%) of patients, respectively. Both treatments were associated with improvements in disease burden and were well tolerated.LimitationsNonrandomized design with potential confounding by indication; decreasing sample sizes at later time points reflecting ongoing registry accrual.ConclusionsBaricitinib and ritlecitinib demonstrated similar scalp hair regrowth in this prospective real-world cohort.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-11-15T09:34:25.365398+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC